Melting point	300 ºC
Specific optical rotation	45 º (C=1, 3N HCl 19 º

SDS/MSDS	S24/25

Source	SDS/MSDS Samples
Alfa-Aesar	View & Download
TCI	View & Download
Oakwood	View & Download

Synthetic Route

More

Name	CAS

More

Articles

Peer-Reviewed Papers

Chronotropic and inotropic actions of amrinone, carbazeran and isobutylmethyl xanthine: role of phosphodiesterase inhibition.M Shahid et al.British journal of pharmacology, 98(1), 291-301 (1989-09-01) A species difference in the presystemic metabolism of carbazeran in dog and man.B Kaye et al.Xenobiotica; the fate of foreign compounds in biological systems, 14(12), 935-945 (1984-12-01) Molecular Cloning and Characterization of Marmoset Aldehyde Oxidase.Shotaro Uehara et al.Drug metabolism and disposition: the biological fate of chemicals, 45(8), 883-886 (2017-05-11) Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment.D J Critchley et al.Xenobiotica; the fate of foreign compounds in biological systems, 24(1), 37-47 (1994-01-01) Application of a Micropatterned Cocultured Hepatocyte System To Predict Preclinical and Human-Specific Drug Metabolism.T Eric Ballard et al.Drug metabolism and disposition: the biological fate of chemicals, 44(2), 172-179 (2015-11-27) Aldehyde oxidase activity in fresh human skin.Nenad Manevski et al.Drug metabolism and disposition: the biological fate of chemicals, 42(12), 2049-2057 (2014-09-25) A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.Jasleen K Sodhi et al.Drug metabolism and disposition: the biological fate of chemicals, 43(6), 908-915 (2015-04-08) Phosphodiesterase inhibitors: haemodynamic effects related to the treatment of cardiac failure.W S Hillis et al.European heart journal, 3 Suppl D, 97-101 (1982-12-01) Oxidative metabolism of carbazeran in vitro by liver cytosol of baboon and man.B Kaye et al.Xenobiotica; the fate of foreign compounds in biological systems, 15(3), 237-242 (1985-03-01) Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs.Raman Sharma et al.Drug metabolism and disposition: the biological fate of chemicals, 40(3), 625-634 (2011-12-23) Comparative pharmacology and clinical efficacy of newer agents in treatment of heart failure.C R Taylor et al.American heart journal, 102(3 Pt 2), 515-532 (1981-09-01) Evaluation of Carbazeran 4-Oxidation and O6-Benzylguanine 8-Oxidation as Catalytic Markers of Human Aldehyde Oxidase: Impact of Cytosolic Contamination of Liver Microsomes.Jiarong Xie et al.Drug metabolism and disposition: the biological fate of chemicals, 47(1), 26-37 (2018-10-20) Drug Metabolism: Towards the Next Millennium, 45-45 (1998) Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver.Maki Miyamoto et al.Xenobiotica; the fate of foreign compounds in biological systems, 47(12), 1052-1063 (2016-11-29) Minipig and Human Metabolism of Aldehyde Oxidase Substrates: In Vitro-In Vivo Comparisons.David J Wilkinson et al.The AAPS journal, 19(4), 1163-1174 (2017-05-06) Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue.B Price et al.Biochemical pharmacology, 36(23), 4047-4054 (1987-12-01) Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes.Shotaro Uehara et al.Drug metabolism and disposition: the biological fate of chemicals, 48(7), 580-586 (2020-05-03) In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.Wee Kiat Tan et al.The Journal of pharmacology and experimental therapeutics, 374(2), 295-307 (2020-05-13) The new inotropic phosphodiesterase inhibitors.D el Allaf et al.Archives internationales de physiologie et de biochimie, 92(4), S69-S79 (1984-11-01)

Remarks